Welcome to our dedicated page for Harmony Biosciences Holdings news (Ticker: HRMY), a resource for investors and traders seeking the latest updates and insights on Harmony Biosciences Holdings stock.
Harmony Biosciences Holdings, Inc. develops and commercializes therapies for rare neurological diseases, with WAKIX® (pitolisant) as its commercial product for adult narcolepsy-associated cataplexy. News about HRMY centers on WAKIX revenue trends, market access and payer dynamics, intellectual-property protection, and product guidance.
Company updates also cover clinical and regulatory progress across its CNS pipeline, including pitolisant lifecycle programs and candidates such as EPX-100 for Dravet syndrome and Lennox-Gastaut syndrome. Recurring announcements include quarterly results, investor-conference presentations, executive and board changes, and pipeline data presentations at medical meetings.
Paragon Biosciences closed the sale of its portfolio company Emalex Biosciences to Teva Pharmaceutical, underscoring its model of advancing registration-ready central nervous system assets. Emalex developed ecopipam, an investigational Tourette syndrome treatment with NDA submission planned for the second half of 2026.
The deal includes $700 million in cash, up to $200 million in commercial milestone payments, and net-sales-based royalties, all subject to regulatory approval. Phase 3 data in Tourette syndrome showed reduced time to relapse versus placebo and maintained clinically meaningful tic improvement.
Harmony Biosciences (Nasdaq: HRMY) will present six posters on narcolepsy and idiopathic hypersomnia at the SLEEP 2026 APSS annual meeting, held June 14–17, 2026, in Baltimore, MD.
Posters cover pitolisant trials, new formulations, HBS-301 studies, patient fatigue, and long-term safety outcomes.
Harmony Biosciences (Nasdaq: HRMY) announced participation in two upcoming investor conferences in Miami, Florida. Management will join fireside chats at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 8:40 a.m. ET and the Oppenheimer CNS & Neuro-Muscular Summit on June 10, 2026, at 3:25 p.m. ET.
A live webcast of both events will be available on Harmony Biosciences’ investor relations website.
Summary not available.
Harmony Biosciences (Nasdaq: HRMY) will report first quarter 2026 financial results on May 7, 2026 before U.S. markets open. Harmony will host a conference call and webcast on May 7 at 8:30 a.m. ET to discuss results; dial-in and webcast details are provided for participants.
Harmony Biosciences (NASDAQ: HRMY) will present encore open-label extension data from the Phase 3 ARGUS trial of EPX-100 (clemizole hydrochloride) for Dravet syndrome at the 2026 AAN Annual Meeting, April 18–22 in Chicago. Poster P10.010 is scheduled for April 22, 2026, 8:00–9:00 AM CT.
The ARGUS trial is currently enrolling; further trial information is available at argustrial.com.
Harmony Biosciences (Nasdaq: HRMY) appointed Glenn Reicin as Chief Financial Officer effective April 14, 2026 and reiterated 2026 net product revenue guidance of $1.0 to $1.04 billion in Wakix sales.
Reicin will oversee finance, FP&A, accounting, treasury, investor relations, and risk management and joins from prior CFO roles where he led IPO readiness and fundraising activities.
Harmony Biosciences (NASDAQ: HRMY) named Peter Anastasiou as Chief Operating Officer and updated its board, appointing Troy Ignelzi and nominating Geno J. Germano for election at the 2026 Annual Meeting.
Mr. Anastasiou resigned from the Board to join the executive team; Antonio Gracias will not stand for re-election. The moves aim to support Harmony's next growth phase and long‑term value creation.
Harmony Biosciences (Nasdaq: HRMY) said its management team will take part in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 9:30 a.m. ET. A live webcast will be available on Harmony's investor relations website.
Harmony Biosciences (Nasdaq: HRMY) said its management team will attend three investor conferences in Miami, FL on March 9–10, 2026: Leerink Partners Global Healthcare Conference, UBS Biotech Summit, and Barclays 28th Annual Global Healthcare Conference.
Investors can expect management presentations and meetings during those dates.